Surgeries & Interventions

Cryoablation as a First-Line AFib Therapy

For people with atrial fibrillation, cryoballoon catheter ablation (cryoablation) as a first-line treatment can halt disease progression and reduce long-term burden. 

Cryoablation involves using extreme cold to kill harmful tissue in the heart and is usually reserved for patients who don’t respond to antiarrhythmic drugs. 

The authors of this NEJM-published study argue that it may be better to start with cryoablation. While AFib begins as an isolated electrical disorder, each recurring incident can cause electrical and structural changes in the heart that can lead to longer-lasting events. In contrast to drug therapies, cryoablation directly targets and destroys the tissue that initiates and perpetuates AFib, and thus can lead to longer lasting results. 


In the study, 303 patients with AFib were randomized to receive either cryoablation or antiarrhythmic drugs. After three years, patients in the cryoablation group had greater improvements than those who received initial antiarrhythmic drug therapy. Early cryoablation was associated with…

  • Fewer episodes of persistent AFib (1.9% vs. 7.4%)
  • Less recurrence of atrial tachyarrhythmia (56.5% vs. 77.2%)
  • Fewer hospitalization events (5.2% vs. 16.8%)
  • Fewer adverse events (4.5% vs. 10.1%)
  • Improvements in quality of life

The Takeaway 

First-line cryoablation led to fewer episodes of persistent AFib, reduced arrhythmia recurrence, lower AFib burden, meaningful improvements in quality of life, lower rates of health care utilization, and lower rates of adverse events. In other words, cryoablation outperformed antiarrhythmic drugs as a first-line defense against AFib. 

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Heart Failure October 20, 2025

Don’t Blame Your Heart for Heart Failure October 20, 2025

Perhaps the biggest cardiology story of the year, an entire issue of JACC now hypothesizes that heart failure with preserved ejection fraction (HFpEF) might actually be caused by visceral fat tissue that triggers cardiac weakening through adipokine signaling. The new unifying adiposity framework now proposes that visceral fat expansion causes secretion of an altered adipokine […]

Cardiology Business October 16, 2025

MedAxiom Report: Cardiologist Compensation Soars, Patient Access Struggles October 16, 2025

Good news and bad news from MedAxiom’s latest cardiology compensation survey. The good news? Cardiologist median compensation reached new record highs last year. The bad news? Patient access deteriorated while the number of patients physicians had to manage swelled. The 2025 survey findings aggregated data across cardiology, cardiac surgery, and vascular surgery specialties, examining compensation […]

Heart Failure October 13, 2025

Specialist Care Can Improve HF Outcomes Across the Board October 13, 2025

A recent study out of the U.K. suggests that multidisciplinary team management could significantly reduce death or rehospitalization risk for HF patients across the LVEF spectrum. Based in a single U.K. county, the Buckinghamshire analysis examined 2.1k patients hospitalized for acute heart failure who received either specialist care or standard care over a 618-day follow-up […]